KRAS and colorectal carcinoma: Interestingly, CRC patients with low expression levels of B4GALT1 showed indeed a significantly shorter PFS duration than patients with high expression levels of B4GALT1 and more so in wild-type (WT)-KRAS patients (p = 0.032 (Figure 4B)) than in KRAS-mutant patients (p = 0.916 (Figure 4C)).